CY1109647T1 - Φαρμακευτικα σκευασματα στερεας μορφης που περιεχουν διασυρεϊνη και μελοξικαμη - Google Patents
Φαρμακευτικα σκευασματα στερεας μορφης που περιεχουν διασυρεϊνη και μελοξικαμηInfo
- Publication number
- CY1109647T1 CY1109647T1 CY20091101203T CY091101203T CY1109647T1 CY 1109647 T1 CY1109647 T1 CY 1109647T1 CY 20091101203 T CY20091101203 T CY 20091101203T CY 091101203 T CY091101203 T CY 091101203T CY 1109647 T1 CY1109647 T1 CY 1109647T1
- Authority
- CY
- Cyprus
- Prior art keywords
- meloxicam
- present
- solid forms
- forms containing
- pharmaceutical solid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Η παρούσα εφεύρεση αφορά φαρμακευτικά σκευάσματα στερεάς μορφής που περιέχουν διασυρεΐνη και μελοξικάμη. Η παρούσα εφεύρεση παρέχει νέα σκευάσματα που περιλαμβάνουν: (α) Διασυρεΐνη, (β) Μελοξικάμη, (γ) ένα ή περισσότερα αντικολλητικά μέσα, (δ) ένα ή περισσότερα μέσα καταθρυμματισμού, (ε) ένα ή περισσότερα συνδετικά μέσα, (στ) ένα ή περισσότερα λιπαντικά, (ζ) ένα ή περισσότερα αραιωτικά μέσα, (η) έναν ή περισσότερους διαλύτες και (θ) οποιοδήποτε άλλο πρόσθετο μπορεί να βοηθήσει το σκεύασμα. Η παρούσα εφεύρεση παρέχει επίσης μια θεραπευτική μέθοδο για την οστεοαρθρίτιδα, τη ρευματοειδή αρθρίτιδα, την ουρική αρθρίτιδα, την πολλαπλή σκλήρυνση, την πλαγία μυατροφική σκλήρυνση και για σχετικές παθήσεις, εκτός των φλεγμονωδών διεργασιών που οφείλονται σε διάφορες αιτιολογίες, μέσω της χορήγησης των κατάλληλων δόσεων.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA04009698A MXPA04009698A (es) | 2004-10-04 | 2004-10-04 | Formulaciones farmaceuticas solidas conteniendo diacereina y meloxicam. |
EP05076453A EP1655026B1 (en) | 2004-10-04 | 2005-06-22 | Solid pharmaceutical formulations comprising diacereine and meloxicam |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1109647T1 true CY1109647T1 (el) | 2014-08-13 |
Family
ID=35427886
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20091101203T CY1109647T1 (el) | 2004-10-04 | 2009-11-18 | Φαρμακευτικα σκευασματα στερεας μορφης που περιεχουν διασυρεϊνη και μελοξικαμη |
Country Status (9)
Country | Link |
---|---|
US (1) | US20060074079A1 (el) |
EP (1) | EP1655026B1 (el) |
AR (1) | AR051318A1 (el) |
AT (1) | ATE439832T1 (el) |
CY (1) | CY1109647T1 (el) |
DE (1) | DE602005016055D1 (el) |
ES (1) | ES2332225T3 (el) |
MX (1) | MXPA04009698A (el) |
PL (1) | PL1655026T3 (el) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA05008575A (es) * | 2005-08-12 | 2007-02-12 | Leopoldo Espinosa Abdala | Formulaciones farmaceuticas solidas sublinguales conteniendo meloxicam. |
MX2007011003A (es) * | 2007-09-07 | 2009-03-09 | World Trade Imp Export Wtie Ag | Composicion farmaceutica que comprende la combinacion de un antiinflamatorio no esteroideo, un relajante muscular de accion central y un inhibidor de la interleucina-1, indicada para el tratamiento de la artritis reumatoide y enfermedades relacionada |
FR2920991A1 (fr) * | 2007-09-14 | 2009-03-20 | Wockhardt Ltd | Composition a base de diacerheine pour le traitement de l'arthrose |
MX2007011931A (es) * | 2007-09-26 | 2009-03-26 | World Trade Imp Export Wtie Ag | Composicion farmaceutica que comprende la combinacion de un agente antiartritico y un agente inhibidor de la interleucina-1, util para el control y tratamiento de la osteoartritis y enfermedades relacionadas. |
TWI473610B (zh) * | 2008-10-28 | 2015-02-21 | Twi Biotechnology Inc | 包含雙醋瑞因(diacerein)之醫藥組合物 |
CA2829101C (en) * | 2011-03-11 | 2019-08-20 | Twi Biotechnology, Inc. | Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia |
MX357376B (es) * | 2011-06-22 | 2018-07-06 | Laboratorios Senosiain S A De C V Star | Composicion farmaceutica para uso en inflamacion y dolor. |
EP2797583B1 (en) * | 2011-12-27 | 2015-09-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Combined pharmaceutical formulation containing diacerein |
CN107929264B (zh) * | 2017-12-04 | 2020-04-24 | 广东药科大学 | 双醋瑞因缓释微球及其制备方法 |
EP4331588A1 (en) * | 2021-04-27 | 2024-03-06 | Animuscure Inc. | Composition for preventing or treating muscular disease, comprising oxicam-based compound |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6610750B1 (en) * | 2000-09-15 | 2003-08-26 | Laboratoires Negma | Treatment of osteoarthritis |
US20020128317A1 (en) * | 2001-01-23 | 2002-09-12 | Laboratories Negma | Treatment of pathological conditions characterized by an increased IL-1 level |
AU2003301121A1 (en) * | 2002-12-18 | 2004-07-14 | Pain Therapeutics, Inc. | Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats |
WO2004062552A2 (en) * | 2003-01-09 | 2004-07-29 | Galephar M/F | Pharmaceutical composition containing a nsaid and a benzimidazole derivative |
US8512727B2 (en) * | 2003-03-03 | 2013-08-20 | Alkermes Pharma Ireland Limited | Nanoparticulate meloxicam formulations |
GB0320382D0 (en) * | 2003-08-30 | 2003-10-01 | West Pharmaceutical Services Drug Delivery & Clinical Research Centre | Pharmaceutical compositions |
-
2004
- 2004-10-04 MX MXPA04009698A patent/MXPA04009698A/es active IP Right Grant
-
2005
- 2005-06-22 PL PL05076453T patent/PL1655026T3/pl unknown
- 2005-06-22 ES ES05076453T patent/ES2332225T3/es active Active
- 2005-06-22 DE DE602005016055T patent/DE602005016055D1/de active Active
- 2005-06-22 EP EP05076453A patent/EP1655026B1/en not_active Not-in-force
- 2005-06-22 AT AT05076453T patent/ATE439832T1/de not_active IP Right Cessation
- 2005-09-30 US US11/186,031 patent/US20060074079A1/en not_active Abandoned
- 2005-10-03 AR ARP050104184A patent/AR051318A1/es not_active Application Discontinuation
-
2009
- 2009-11-18 CY CY20091101203T patent/CY1109647T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
US20060074079A1 (en) | 2006-04-06 |
EP1655026B1 (en) | 2009-08-19 |
ES2332225T3 (es) | 2010-01-29 |
MXPA04009698A (es) | 2006-04-05 |
EP1655026A1 (en) | 2006-05-10 |
PL1655026T3 (pl) | 2010-01-29 |
AR051318A1 (es) | 2007-01-03 |
DE602005016055D1 (de) | 2009-10-01 |
ATE439832T1 (de) | 2009-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1109647T1 (el) | Φαρμακευτικα σκευασματα στερεας μορφης που περιεχουν διασυρεϊνη και μελοξικαμη | |
FIC20210022I1 (fi) | tukatinibi, valinnaisesti farmaseuttisesti hyväksyttävän suolan tai solvaatin muodossa | |
EA200802058A1 (ru) | Производные циклоалкиламинокислот и их фармацевтические композиции | |
CY1107301T1 (el) | Ιμιδαζο και θειαζολοπυριδινες ως αναστολεις κινασης jak3 | |
EA200900959A1 (ru) | Ингибиторы мек | |
EA200501327A1 (ru) | Пиримидины и триазины, ингибирующие вич репликацию | |
CY1116548T1 (el) | Χρηση παραγωγων 1,3-διφαινυλπροπ-2-εν-1-ονης για την αγωγη ηπατικων διαταραχων | |
DK2111401T3 (da) | 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl)phenyl]-1H-pyrazol-5-yl}carbamoyl)-amino]-3-fluorphenoxy}-N-methylpyridin-2-carboxamid samt prodrug og salte heraf til behandling af cancer | |
CY1110318T1 (el) | Παραγωγα φαινοξυοξικου οξεος | |
EA201800064A1 (ru) | 1,1,1-трифтор-3-гидроксипропан-2-ил карбаматные производные и 1,1,1-трифтор-4-гидроксибутан-2-ил карбаматные производные в качестве ингибиторов magl | |
ATE542818T1 (de) | Imidazo- und triazolopyridinverbindungen und verfahren zu deren anwendung | |
CY1111670T1 (el) | Αζετιδινες ως αναστολεις μεκ για τη θεραπευτικη αγωγη πολλαπλασιαστικων ασθενειων | |
EA201070148A1 (ru) | Соединения и способы модулирования фарнезоидного рецептора x (fxr) | |
DK1689233T3 (da) | Bicykliske inhibitorer af MEK | |
EA200501713A1 (ru) | Фенилзамещённые карбоновые кислоты | |
CY1105362T1 (el) | Παραγωγα σουλφοναμιδιου, η παρασκευη τους και η εφαρμογη αυτων ως φαρμακα | |
CY1113159T1 (el) | Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις | |
CY1107473T1 (el) | Ενα παραγωγο pyridine-n-oxide, και διαδικασια για τη μετατροπη του σε αποτελεσματικες φαρμακευτικες συνθεσεις | |
EA201991700A1 (ru) | Селективные ингибиторы jak1 | |
CY1108625T1 (el) | Φαρμακευτικες συνθεσεις για τη χορηγηση απο το στομα ηπαρινης ή παραγωγων της | |
CY1109465T1 (el) | Νεες φαρμακευτικες φαρμακοτεχνικες μορφες μονταφινιλης | |
CY1113533T1 (el) | Ετεροαρυλο-υποκατεστημενα παραγωγα κυκλοεξυλο-1,4-διαμινης | |
EA200800393A1 (ru) | Новые соединения-аналоги камптотецина, способ их получения и фармацевтические композиции, которые их содержат | |
BRPI0409454A (pt) | compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com o receptor de glucagon e sua utilização | |
BRPI0517369A (pt) | compostos, processo para a sua manufatura, composições que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização |